Leadership Transition at PharmAust

PharmAust Limited (ASX: PAA) has announced the resignation of CEO Dr. Michael Thurn, effective in four months, citing personal reasons. Dr. Thurn has been instrumental in advancing the company's monepantel (MPL) program for motor neuron disease (MND/ALS), leading Phase 1 studies and preparing for Phase 2/3 trials, in addition to managing shareholder relations and capital raises.

John Clark, the current Chief Operating Officer with over 20 years of experience in pharmaceutical clinical trials, has been named interim CEO. Clark has a strong track record in project management and stakeholder engagement across various therapeutic areas and geographies. The company is poised to continue its focus on the clinical development and planned commercialization of MPL under Clark’s leadership.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com